Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
Importance: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.
Objective: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.
Design, Setting, and Participants: Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022.
Interventions: Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401).
Main Outcomes and Measures: The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83.
Results: Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies.
Conclusions and Relevance: Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:329 |
|---|---|
| Enthalten in: |
JAMA - 329(2023), 1 vom: 03. Jan., Seite 39-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Writing Committee for the REMAP-CAP Investigators [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 05.01.2023 Date Revised 28.12.2023 published: Print CommentIn: JAMA. 2023 Jan 3;329(1):25-27. - PMID 36525259 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jama.2022.23257 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350371687 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350371687 | ||
| 003 | DE-627 | ||
| 005 | 20231229124102.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2022.23257 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM350371687 | ||
| 035 | |a (NLM)36525245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Writing Committee for the REMAP-CAP Investigators |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2023 | ||
| 500 | |a Date Revised 28.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: JAMA. 2023 Jan 3;329(1):25-27. - PMID 36525259 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown | ||
| 520 | |a Objective: To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes | ||
| 520 | |a Design, Setting, and Participants: Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022 | ||
| 520 | |a Interventions: Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401) | ||
| 520 | |a Main Outcomes and Measures: The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83 | ||
| 520 | |a Results: Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies | ||
| 520 | |a Conclusions and Relevance: Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 700 | 1 | |a Higgins, Alisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Lindsay R |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzi, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a McQuilten, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Mouncey, Paul R |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Beidh, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Annane, Djillali |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M |e verfasserin |4 aut | |
| 700 | 1 | |a Beane, Abi |e verfasserin |4 aut | |
| 700 | 1 | |a van Bentum-Puijk, Wilma |e verfasserin |4 aut | |
| 700 | 1 | |a Bhimani, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Bonten, Marc J M |e verfasserin |4 aut | |
| 700 | 1 | |a Bradbury, Charlotte A |e verfasserin |4 aut | |
| 700 | 1 | |a Brunkhorst, Frank M |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Buzgau, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Buxton, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Walton N |e verfasserin |4 aut | |
| 700 | 1 | |a Cove, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Detry, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Estcourt, Lise J |e verfasserin |4 aut | |
| 700 | 1 | |a Fagbodun, Elizabeth O |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Girard, Timothy D |e verfasserin |4 aut | |
| 700 | 1 | |a Goligher, Ewan C |e verfasserin |4 aut | |
| 700 | 1 | |a Goossens, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Haniffa, Rashan |e verfasserin |4 aut | |
| 700 | 1 | |a Hills, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Horvat, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Ichihara, Nao |e verfasserin |4 aut | |
| 700 | 1 | |a Lamontagne, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John C |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a McGlothlin, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a McGuinness, Shay P |e verfasserin |4 aut | |
| 700 | 1 | |a McVerry, Bryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Neal, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Nichol, Alistair D |e verfasserin |4 aut | |
| 700 | 1 | |a Parke, Rachael L |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Jane C |e verfasserin |4 aut | |
| 700 | 1 | |a Parry-Billings, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Sam E C |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Luis F |e verfasserin |4 aut | |
| 700 | 1 | |a Rowan, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Marlene S |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Christina T |e verfasserin |4 aut | |
| 700 | 1 | |a Serpa-Neto, Ary |e verfasserin |4 aut | |
| 700 | 1 | |a Seymour, Christopher W |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar-Hari, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a Stronach, Lucy M |e verfasserin |4 aut | |
| 700 | 1 | |a Turgeon, Alexis F |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Anne M |e verfasserin |4 aut | |
| 700 | 1 | |a van de Veerdonk, Frank L |e verfasserin |4 aut | |
| 700 | 1 | |a Zarychanski, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Roger J |e verfasserin |4 aut | |
| 700 | 1 | |a Angus, Derek C |e verfasserin |4 aut | |
| 700 | 1 | |a McArthur, Colin J |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Derde, Lennie P G |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Steve A |e verfasserin |4 aut | |
| 700 | 1 | |a Lawler, Patrick R |e verfasserin |4 aut | |
| 700 | 1 | |a Florescu, Simin |e investigator |4 oth | |
| 700 | 1 | |a Stanciu, Delia |e investigator |4 oth | |
| 700 | 1 | |a Zaharia, Mihaela |e investigator |4 oth | |
| 700 | 1 | |a Kosa, Alma |e investigator |4 oth | |
| 700 | 1 | |a Codreanu, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Kidwai, Aneela |e investigator |4 oth | |
| 700 | 1 | |a Masood, Sobia |e investigator |4 oth | |
| 700 | 1 | |a Kaye, Callum |e investigator |4 oth | |
| 700 | 1 | |a Coutts, Amanda |e investigator |4 oth | |
| 700 | 1 | |a MacKay, Lynn |e investigator |4 oth | |
| 700 | 1 | |a Summers, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Polgarova, Petra |e investigator |4 oth | |
| 700 | 1 | |a Farahi, Neda |e investigator |4 oth | |
| 700 | 1 | |a Fox, Eleonore |e investigator |4 oth | |
| 700 | 1 | |a McWilliam, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Hawcutt, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Rad, Laura |e investigator |4 oth | |
| 700 | 1 | |a O'Malley, Laura |e investigator |4 oth | |
| 700 | 1 | |a Whitbread, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Jones, Dawn |e investigator |4 oth | |
| 700 | 1 | |a Dore, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Saunderson, Paula |e investigator |4 oth | |
| 700 | 1 | |a Kelsall, Olivia |e investigator |4 oth | |
| 700 | 1 | |a Cowley, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Wild, Laura |e investigator |4 oth | |
| 700 | 1 | |a Thrush, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Wood, Hannah |e investigator |4 oth | |
| 700 | 1 | |a Austin, Karen |e investigator |4 oth | |
| 700 | 1 | |a Bélteczki, János |e investigator |4 oth | |
| 700 | 1 | |a Magyar, István |e investigator |4 oth | |
| 700 | 1 | |a Fazekas, Ágnes |e investigator |4 oth | |
| 700 | 1 | |a Kovács, Sándor |e investigator |4 oth | |
| 700 | 1 | |a Szőke, Viktória |e investigator |4 oth | |
| 700 | 1 | |a Donnelly, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Kelly, Martin |e investigator |4 oth | |
| 700 | 1 | |a Smyth, Naoise |e investigator |4 oth | |
| 700 | 1 | |a O'Kane, Sinéad |e investigator |4 oth | |
| 700 | 1 | |a McClintock, Declan |e investigator |4 oth | |
| 700 | 1 | |a Warnock, Majella |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Ryan |e investigator |4 oth | |
| 700 | 1 | |a McCallion, Edmund |e investigator |4 oth | |
| 700 | 1 | |a Azaiz, Amine |e investigator |4 oth | |
| 700 | 1 | |a Charron, Cyril |e investigator |4 oth | |
| 700 | 1 | |a Godement, Mathieu |e investigator |4 oth | |
| 700 | 1 | |a Geri, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Vieillard-Baron, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Paul |e investigator |4 oth | |
| 700 | 1 | |a McKenna, Shirley |e investigator |4 oth | |
| 700 | 1 | |a Hanley, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Currie, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Allen, Barbara |e investigator |4 oth | |
| 700 | 1 | |a McGoldrick, Clare |e investigator |4 oth | |
| 700 | 1 | |a McMaster, Moyra |e investigator |4 oth | |
| 700 | 1 | |a Mani, Ashwin |e investigator |4 oth | |
| 700 | 1 | |a Mathew, Meghena |e investigator |4 oth | |
| 700 | 1 | |a Kandeepan, Revathi |e investigator |4 oth | |
| 700 | 1 | |a Vignesh, C |e investigator |4 oth | |
| 700 | 1 | |a Tv, Bharath |e investigator |4 oth | |
| 700 | 1 | |a Ramakrishnan, N |e investigator |4 oth | |
| 700 | 1 | |a James, Augustian |e investigator |4 oth | |
| 700 | 1 | |a Elvira, Evangeline |e investigator |4 oth | |
| 700 | 1 | |a Jayakumar, Devachandran |e investigator |4 oth | |
| 700 | 1 | |a Pratheema, Ramachandran |e investigator |4 oth | |
| 700 | 1 | |a Babu, Suresh |e investigator |4 oth | |
| 700 | 1 | |a Ebenezer, R |e investigator |4 oth | |
| 700 | 1 | |a Krishnaoorthy, S |e investigator |4 oth | |
| 700 | 1 | |a Ranganathan, Lakshmi |e investigator |4 oth | |
| 700 | 1 | |a Ganesan, Manisha |e investigator |4 oth | |
| 700 | 1 | |a Shree, Madhu |e investigator |4 oth | |
| 700 | 1 | |a Guilder, Eileen |e investigator |4 oth | |
| 700 | 1 | |a Butler, Magdalena |e investigator |4 oth | |
| 700 | 1 | |a Cowdrey, Keri-Anne |e investigator |4 oth | |
| 700 | 1 | |a Robertson, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Ali, Farisha |e investigator |4 oth | |
| 700 | 1 | |a McMahon, Ellie |e investigator |4 oth | |
| 700 | 1 | |a Duffy, Eamon |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yan |e investigator |4 oth | |
| 700 | 1 | |a Simmonds, Catherine |e investigator |4 oth | |
| 700 | 1 | |a McConnochie, Rachael |e investigator |4 oth | |
| 700 | 1 | |a O'Connor, Caroline |e investigator |4 oth | |
| 700 | 1 | |a El-Khawas, Khaled |e investigator |4 oth | |
| 700 | 1 | |a Richardson, Angus |e investigator |4 oth | |
| 700 | 1 | |a Hill, Dianne |e investigator |4 oth | |
| 700 | 1 | |a Commons, Robert |e investigator |4 oth | |
| 700 | 1 | |a Abdelkharim, Hussam |e investigator |4 oth | |
| 700 | 1 | |a Saxena, Manoj |e investigator |4 oth | |
| 700 | 1 | |a Muteithia, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Dobell-Brown, Kelsey |e investigator |4 oth | |
| 700 | 1 | |a Jha, Rajeev |e investigator |4 oth | |
| 700 | 1 | |a Kalogirou, Michael |e investigator |4 oth | |
| 700 | 1 | |a Ellis, Christine |e investigator |4 oth | |
| 700 | 1 | |a Krishnamurthy, Vinodh |e investigator |4 oth | |
| 700 | 1 | |a O'Connor, Aibhilin |e investigator |4 oth | |
| 700 | 1 | |a Thurairatnam, Saranya |e investigator |4 oth | |
| 700 | 1 | |a Mukherjee, Dipak |e investigator |4 oth | |
| 700 | 1 | |a Kaliappan, Agilan |e investigator |4 oth | |
| 700 | 1 | |a Vertue, Mark |e investigator |4 oth | |
| 700 | 1 | |a Nicholson, Anne |e investigator |4 oth | |
| 700 | 1 | |a Riches, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Maloney, Gracie |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA |d 1948 |g 329(2023), 1 vom: 03. Jan., Seite 39-51 |w (DE-627)NLM000006939 |x 1538-3598 |7 nnns |
| 773 | 1 | 8 | |g volume:329 |g year:2023 |g number:1 |g day:03 |g month:01 |g pages:39-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2022.23257 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 329 |j 2023 |e 1 |b 03 |c 01 |h 39-51 | ||